Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection
Status: | Completed |
---|---|
Conditions: | Influenza |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/1/2014 |
Start Date: | December 2013 |
End Date: | February 2015 |
Email: | JNJ.CT@sylogent.com |
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection
The purpose of this study is to evaluate the rate of decline in quantitative viral load
measured in hospitalized patients with Influenza A infection
measured in hospitalized patients with Influenza A infection
This is a randomized, placebo-controlled, double-blind phase IIa proof-of-concept study,
designed to evaluate the effect of CR8020, CR6261, or placebo in hospitalized patients with
influenza A infection that are receiving standard of care. Up to 262 participants will be
randomized to receive 30 mg/kg of CR8020, 30 mg/kg of CR6261, or placebo. The study duration
will be approximately 117 days for each participant. Prior to enrollment, participants will
be screened to assess their eligibility. Eligible participants will be randomized to CR8020,
CR6261, or placebo and study drug will be administered on Day 1. Participants will be
followed up for 115 days in 9 visits on Days 2 to 8, Day 29, and Day 116 (end of study).
After hospital discharge, the remaining follow-up visits will be performed as outpatient
visits.
designed to evaluate the effect of CR8020, CR6261, or placebo in hospitalized patients with
influenza A infection that are receiving standard of care. Up to 262 participants will be
randomized to receive 30 mg/kg of CR8020, 30 mg/kg of CR6261, or placebo. The study duration
will be approximately 117 days for each participant. Prior to enrollment, participants will
be screened to assess their eligibility. Eligible participants will be randomized to CR8020,
CR6261, or placebo and study drug will be administered on Day 1. Participants will be
followed up for 115 days in 9 visits on Days 2 to 8, Day 29, and Day 116 (end of study).
After hospital discharge, the remaining follow-up visits will be performed as outpatient
visits.
Inclusion Criteria:
Participant requires hospitalization/ Each participant or his or her legally acceptable
representative must sign an informed consent form/ Participant must be able to start the
infusion within 36 hours from the time the screening specimen was collected/ A woman must
either be not of childbearing potential or of childbearing potential and agrees to
practice two forms of highly effective method of birth control/ A woman of childbearing
potential must have a negative serum (beta human chorionic gonadotropin [beta hCG]) at
screening/ A man who is sexually active with a woman of childbearing potential and has not
had a vasectomy must agree to use a barrier method of birth control/
Exclusion Criteria:
Participant is a female who is pregnant or breastfeeding/ Participant undergoing
peritoneal dialysis, hemodialysis or hemofiltration/ Participant has presence of any
pre-existing illness that, in the opinion of the investigator, would place the participant
at an unreasonably increased risk through participation in this study/ Participant has
prior treatment with an experimental mAb; or receipt of IgG within 3 months or on chronic
mAb treatment prior to enrollment/ Participant has known or suspected hypersensitivity to
any of the CR8020 or CR6261 excipients (sucrose, L-histidine L-histidine
monohydrochloride, polysorbate 20)/ Participant received an investigational product
(including investigational vaccines) or used an investigational medical device within 60
days before the planned start of treatment, is currently enrolled in an interventional
investigational study, or is an employee of the investigational site/
We found this trial at
30
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials